Skip to content
Oncoinfo路 @Oncoinfo_it 路 X路路 14 hours agoScore70

TALENT

Body 路 original

#ESMO26 | Armando Orlandi commenta i risultati dello studio TALENT su T-DXd nelle pazienti con carcinoma mammario HR+/HER2-low in fase neoadiuvante馃憞
#OncoSTEPS #earlybreastcancer #eBC

40 views 路 0 likes 路 0 reposts 路 0 replies

Conference abstracts
LBA23matched by Proffered paper 1: Breast cancer, early and advanced stage

Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer

https://esmocongress.esmo.org

Source: Oncoinfo 路 x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org